Mecolvix (Mesalazine)

Mesalazine acts locally in the colon to inhibit cyclooxygenase and lipoxygenase enzymes, reducing prostaglandin and leukotriene production. It also modulates immune cell activity, decreasing cytokine release and stabilising the mucosal barrier, which together lessen intestinal inflammation.

The dosage of Mecolvix is determined by the prescribing clinician based on the severity of ulcerative colitis, patient weight, and response to therapy. Specific dosing regimens are not provided here and should follow the prescriber’s instructions.

Safety data for mesalazine in pregnancy and lactation are limited. Mecolvix should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by the treating physician.

To order Mecolvix, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mecolvix (mesalazine) is a 5‑ASA agent that provides a topical anti‑inflammatory effect, whereas systemic steroids or biologics act more broadly. Compared with oral mesalazine, the rectal formulation delivers higher local concentrations with fewer systemic side effects, making it suitable for distal disease.

Mecolvix should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing in humid environments.

Mecolvix is administered rectally, typically as an enema or suppository, according to the prescribing information. The patient should follow the healthcare provider’s instructions on dosage volume, frequency and positioning to ensure optimal drug delivery to the colon.

Serious risks include severe allergic reactions such as anaphylaxis, acute severe colitis with bloody stools, liver injury, pancreatitis, and rare skin disorders like Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience any of these symptoms.

Mecolvix should be avoided in patients with known hypersensitivity to mesalazine or any component of the formulation, in those with severe renal or hepatic impairment unless closely monitored, and in individuals where the risk of serious adverse reactions outweighs potential benefits.